Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
Jenny Ng, 2 years ago

First results from the ALTTO trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) shows no benefit of adding lapatinib to standard trastuzumab adjuvant therapy in women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Jairia Dela Cruz, one year ago
Neither a specific diagnostic approach nor “a gender-driven” therapy is currently available for women with lung cancer, according to an expert who discussed existing assumptions and evidence at the recent Asia Pacific Lung Cancer Conference 2016.
Kavitha G. Shekar, one year ago

Erdosteine protects lung cancer patients against cisplatin-induced nephrotoxicity, say researchers at the recent IASLC Asia Pacific Lung Cancer Conference (APLCC) 2016 in Chiang Mai, Thailand.